Mycophenolate mofetil (MMF) has recently been reported to be effective in the treatment of
systemic lupus erythematosus (SLE). The therapeutic range of
mycophenolic acid (MPA) and its 7-O-glucuronide (MPAG), and factors affecting their pharmacokinetics, remain to be clarified. The influence of the pharmacokinetics of MPA and MPAG on the activity of
inosine 5'-monophosphate
dehydrogenase (IMPDH), a target of the MPA, also remains to be revealed. The pharmacokinetic variability of hydroxy-
itraconazole (
OH-ITZ), an active metabolite of
itraconazole frequently co-administered with
immunosuppressants in immunocompromised patients, is not fully known. The aim of this study was to establish the optimal dosage and administration of
immunosuppressants and
antifungal agents. MMF improved clinical laboratory markers and reduced
prednisolone dosage in 31 SLE patients, with a pre-dose plasma concentration of MPA and MPAG in the interquartile ranges of 0.94-2.96 and 18.6-53.7 μg/mL, respectively. Renal function and co-administered
metal influenced the pharmacokinetics of MPA and MPAG in 31 SLE patients in the remission maintenance phase. IMPDH activity was induced in 29 SLE patients receiving the MMF
therapy. This induction was dependent on the plasma concentration of MPAG, but not MPA. In addition, IMPDH activity was negatively correlated with
complement fraction C3. MPA exposure and disease activity in SLE patients may determine IMPDH activity. The pharmacokinetic variability of
OH-ITZ was associated with saturated metabolism to keto-
itraconazole, serum concentration of
albumin, and renal function in 46 immunocompromised patients. Prevention of
fungal infections and
drug-drug interactions in immunocompromised patients can be obtained by considering these identified confounding factors.